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ABSTRACT
Introduction: The aim of this study was to
examine the influence of weight change
experiences over time on motivation to
perform diabetes self-care behaviors using data
from a study of canagliflozin (an agent that
inhibits sodium glucose co-transporter 2) versus
glimepiride in dual therapy with metformin
and background diet/exercise.
Methods: Weight and motivation for
performing healthy behaviors were collected at
baseline and over time. The motivation
questionnaire enabled categorization into two
groups: those performing or not performing
health behaviors. Four distinct patterns of
weight change were determined: losing
weight, gaining weight, and two patterns for
fluctuating weight. The relationships between
these patterns and motivation for weight loss,
following a diet, and exercise were examined
using logistic regression models.
Results: Of 1182 subjects, more than half were
already performing behaviors to lose weight,
diet, and exercise at baseline. Among those who
were not, 52% (246/474) started taking action
to lose weight after baseline, 54% (241/448)
started following a diet, and 42% (232/556)
started exercising. Weight change patterns were
significantly related to performance of healthy
behaviors at follow-up (week 36). Compared to
the weight gain pattern, those who experienced
a continuous weight loss pattern from baseline
to week 36 were 2.2 (95% confidence interval
1.49, 3.37) times more likely to perform the
healthy behaviors. Baseline behavior and
confidence were also predictive of performing
healthy behaviors.
Conclusion: The current work highlights the
importance of weight change patterns for
performance of diabetes self-care. Tracking
weight patterns over time, assessing
confidence for performance of healthy
behaviors, and being aware of the relationship
between weight changes and diabetes self-care
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behaviors are viable, concrete ways to practice
patient-centered care.
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INTRODUCTION
Type 2 diabetes is primarily a self-managed
disease. Self-care behaviors, such as following a
healthy diet, being physically active, taking
medications as prescribed, and monitoring
health (e.g., glucose levels, body weight, blood
pressure) [1], are an important part of achieving
optimal outcomes and can have a major impact
on the lives of patients, their families, and
society [2]. For a person to adhere to self-care
activities, he or she must have the knowledge
and skill to perform these activities, the
confidence (i.e., self-efficacy [3]) and
motivation to do so, and the belief that
performance will be beneficial for managing
the disease. Determinants of self-care include
cultural [4], psychosocial [5], physical [6], and
economic [7] aspects. Treatments can also
influence behavior through their impact on
factors such as glucose control, weight, blood
pressure, and hypoglycemia. Experiencing
benefits can be encouraging and may lead to
increased performance of healthy behaviors,
thus continuing the cycle of realized benefits
and reinforcing the behaviors. Conversely,
drawbacks associated with treatments may
deter performance of healthy behaviors.
Continuous reinforcement of healthy
behaviors, as well as continued or maintained
weight loss, has been shown to increase
motivation [8]. Motivational Interviewing (MI)
is a directive, person-centered intervention
designed to explore ambivalence/resistance to
behavior change, support self-efficacy, and
activate motivation to perform target
behaviors in a nonjudgemental way [9, 10].
Studies have shown that MI can contribute to
improvements in self-management abilities and
outcomes among people with type 2 diabetes [3,
11].
MI has been employed by health
professionals to assess a person’s readiness to
make a behavioral change (RTC) and to help
people maintain performance of diabetes
self-care behaviors. Five stages of RTC are
described by the transtheoretical model (TTM)
[12]. The TTM focuses on the decision-making
of the individual and is a model of intentional
change. The TTM posits that individuals move
through five stages of change:
precontemplation (e.g., a healthier lifestyle is
not yet considered), contemplation (e.g.,
thinking about behavior change), preparation
(e.g., intending to but not yet taking action),
action (e.g., starting to modify behaviors in the
last 6 months), and maintenance (e.g.,
stabilizing behavior change and avoiding
relapse over [6 months). For each stage of
change, different intervention strategies are
likely more effective in moving the person to
the next stage of change and ultimately to
maintenance [13]. The TTM dichotomizes the
five stages of RTC into pre-Action (i.e.,
precontemplation, contemplation, and
preparation) and Action (i.e., action and
maintenance) stages [14].
The TTM assumes that behavior changes are
cyclical. This means that people living with type
2 diabetes can move forward and backward
through the stages of RTC. This is often referred
to as recycling, which can occur multiple times
before changing for good. Recycling is not
failing, but a natural occurrence that may be
helpful in inducing lifelong behavioral changes,
since individuals tend to have a heightened
focus on barriers or challenges during these
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times. People can simultaneously be at different
RTC stages for individual behaviors, such as
engaging in weight loss/maintenance, healthy
eating, and exercise. Assessing the stage of
change for each target behavior is particularly
important for guiding and evaluating
interventions [15]. Research has indicated that
interventions tailored to the individual’s stage
of change work better than generic approaches
[16]. Moving to the Action stages of RTC for
diabetes-specific behaviors has been related to
reductions in HbA1c [17].
Findings from qualitative interviews among
people with type 2 diabetes suggest that
individual experiences are complex and
influenced by cognitive, behavioral, and
emotional dimensions that are linked with all
aspects of peoples’ daily lives [18]. How people
feel about their weight has been posited to be an
important driver of behavior. A recent empirical
study showed that satisfaction with weight was
strongly associated with positive behaviors and
outcomes [19]. In our previous work, we found
that weight loss led to improvements in
self-reported weight-related quality of life and
satisfaction with health, which are associated
with consistent and persistent performance of
healthy behaviors [20]. In that study, for
simplicity, participants were classified into two
groups: \5 or C5 pounds of weight loss [20].
Note, any threshold chosen is not meaningful
for all people; what one person perceives as a
meaningful change may not be meaningful to
another. In addition, different patterns of
response may produce the same change over
time, but very different experiences. For
example, losing 5 pounds and then gaining it
back for a net change of zero is a different
experience than never having changed weight.
The experience of regaining weight may be
more discouraging than maintaining the same
weight. The insights gained from our previous
study [20] highlight the need to shift focus from
‘‘clinically meaningful’’ weight loss (i.e.,
sufficient weight loss to impact a clinical
outcome) to the patient experience of weight
loss, which is more relevant for patient-reported
outcomes. Defining arbitrary thresholds for
weight loss is not useful when the goal is to
describe the amount of weight loss that will
motivate an individual to adopt and maintain
healthy behaviors. Furthermore, understanding
which weight change pattern a person has
experienced is important for encouraging
target behaviors.
However, it is challenging to get a clear
picture of a person’s experience with weight
change because the methods used in current
practice typically rely on weight measurements
at clinic visits that are several months apart.
Measurement of net weight change does not
take into account trends and experiences over
time; between visits, a person may have
experienced noticeable weight gains and/or
losses. When considering randomized
controlled trial results to assist in treatment
selection, it is important to recognize that
reported mean changes do not address the
heterogeneity of treatment effects, or trends
over time [21].
The current study explores the empirical
relationship between weight change
experiences and RTC behavior, using an




This analysis is based on results from a
104-week, randomized, double-blind, Phase 3
study that assessed the efficacy and safety of
canagliflozin 100 and 300 mg versus maximally
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tolerated doses of glimepiride in subjects with
type 2 diabetes inadequately controlled with
metformin and background diet and exercise
[22, 23]. Canagliflozin (an agent that inhibits
sodium glucose co-transporter 2 [SGLT2]) has
been shown to significantly reduce HbA1c,
body weight, and blood pressure. Canagliflozin
has been associated with adverse events (AEs)
related to the mechanism of action (e.g., genital
mycotic infections, urinary tract infections, and
AEs related to volume depletion and osmotic
diuresis); however, canagliflozin has been
shown to be well tolerated, as these events led
to few discontinuations in the clinical trial
program [22, 23]. Glimepiride has also been
shown to significantly reduce HbA1c; however,
it has been associated with weight gain and an
increase in hypoglycemia [2]. In this trial,
canagliflozin 300 mg demonstrated superiority,
and canagliflozin 100 mg demonstrated
noninferiority, to glimepiride in HbA1c
lowering at 52 weeks [22]; these effects
were maintained at 104 weeks [23]. Both
canagliflozin doses were associated with a
mean weight loss of 3.6 kg and glimepiride
was associated with a mean weight gain of
0.8 kg at week 104 [23].
Weight, RTC behavior, the effect of weight
on quality of life, and self-efficacy for healthy
behaviors were measured at baseline and over
time. Specifically, body weight was measured at
baseline and during clinic visits at weeks 4, 8,
12, 18, 26, 36, 44, and 52. RTC behavior was
measured at baseline and weeks 4, 8, and 36
using individual items that were developed to
identify a respondent’s TTM stage of change for
weight loss, exercise, and following a diet. For
each self-care behavior, five response options
were provided to map the five stages of RTC (see
Fig. S1 in the supplementary material). The
effect of weight on quality of life was measured
using the Impact of Weight on Quality of
Life–Lite (IWQoL-Lite) questionnaire [24] at
baseline and week 52. This instrument assesses
the impact of weight on several domains of
quality of life, including physical function,
self-esteem, sexual life, public distress, and
work, which are measured on a scale from 0
(highest burden) to 100 (lowest burden).
Self-efficacy for healthy behaviors was
measured using the Multidimensional Diabetes
Questionnaire (MDQ) at baseline and weeks 4,
8, and 36. This instrument captures self-efficacy
for the ability to maintain a healthy weight,
follow a diet, and resist food temptations [25].
For simplicity, scales were dichotomized above
and below the midpoint, where scores above
the midpoint indicate a greater degree of
self-efficacy. For weight loss and exercise,
self-efficacy was measured using only one item
each. For diet, two items that related to
following a diet and resisting food temptations
were combined ([midpoint on both items
versus [midpoint on zero or one item). A
check box was provided for respondents to
indicate whether they were advised not to
exercise; we used this to exclude subjects from
the exercise behavior outcome analyses.
Weight Change Patterns
Randomized clinical trials often summarize the
effect of an intervention on weight using mean
within-patient change values to describe the
change from baseline to subsequent time
points. However, this calculation does not
reflect individual experiences of weight change
over time, making it difficult for health care
professionals to apply this to individuals. Also,
perceptions of weight change are not
necessarily linear. Lane et al. [26] showed that
weight gain had a larger negative impact on
people with type 2 diabetes than the positive
impact of the same amount of weight loss.
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To determine patterns of weight change in
individuals, a clustering algorithm [27] was
applied to pooled, individual weight change
data over time from three trials (not including
the trial that was analyzed in this report)
[28–30]. Additional details are provided in
Appendix 1 in the supplementary material.
This analysis suggested that subjects
experienced steady weight gain, steady weight
loss, initial weight loss followed by weight gain,
or initial weight gain followed by weight loss.
As a result of these findings, we defined the
experience of weight change over time using
four patterns, as follows:
• Pattern 1: lost any weight from baseline to
week 18, and lost any weight from week 18
to 36;
• Pattern 2: lost any weight from baseline to
week 18, and gained any weight or did not
change weight from week 18 to 36;
• Pattern 3: gained any weight or did not
change weight from baseline to week 18, and
lost any weight from week 18 to 36;
• Pattern 4: gained any weight or did not
change weight from baseline to week 18, and
gained any weight or did not change weight
from week 18 to 36.
Additional details on the derivation of these
patterns are provided in Appendix 1 in the
supplementary material.
Statistical Methods
The primary outcome was ‘Action’ stage versus
‘pre-Action’ stage for each self-care behavior at
week 36. Univariate associations between
baseline sociodemographic, clinical, and
patient-reported characteristics and RTC stage
were compared using the t test or chi-square
test, as appropriate. The relationships between
weight change patterns and maintenance of or
movement into the Action stage of RTC at week
36 were examined for three health behaviors
(engaging in weight loss, following a diabetes
diet, and exercise) using logistic regression
models. Baseline RTC and self-efficacy were
included because previous work has shown
that past behavior predicts future behavior
[31], and self-efficacy has been linked to
performance of behaviors [3]. Other covariate
adjustments included age, gender, race, baseline
body mass index (BMI), and baseline HbA1c
(%). Smoking status and history of depression
were included, as these factors may impact the
performance of the health behaviors of interest.
Overall functional status was accounted for
with the Short-Form 36 (SF-36) physical and
mental component summary scores [32];
weight-related self-esteem was included as a
continuous covariate and weight-related
physical function was dichotomized into those
who were in the lowest quartile (most impaired)
versus the top three quartiles.
RESULTS
Of 1182 subjects with RTC data at baseline and
week 36, more than half were taking Action for
weight loss, diet, and exercise at baseline,
respectively (n = 1174 for exercise; excludes
eight who were advised not to exercise). At
baseline, 32% of subjects were taking Action for
all three behaviors and 16% were not taking
Action for any of the three behaviors. Those
taking Action for weight loss at baseline were
more likely to be male, less likely to be
Caucasian, and had higher self-efficacy for all
three self-care behaviors. Among those already
taking Action for weight loss, 71% were also
taking Action for following a diet and 66% were
also taking Action for exercise. Those taking
Action for diet at baseline were similar, but
additionally had a lower average BMI and better
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health-related quality of life. The greatest
difference in BMI was observed between
baseline Action and pre-Action for exercise.
HbA1c only differed by baseline RTC for diet,
but not for weight loss or exercise (Table 1).
For each behavior, the net proportion of
subjects in Action increased between baseline
and week 36 by about 10% (Table 2).
Relationships between Action and pre-Action
at week 36 and demographic, clinical, and
patient-reported variables were generally
similar to associations observed at baseline.
Among subjects randomized to canagliflozin,
72% were taking Action for weight loss at week
36 versus 65% for glimepiride (P = 0.015).
Among subjects randomized to canagliflozin,
78% were taking Action for diet at week 36
versus 72% for glimepiride (P = 0.051). For
exercise, the proportion taking Action at week
36 was not statistically different by treatment
assignment (67% and 64%, respectively).
In examining body weight through week
36, it was observed that 40% of subjects
experienced weight change Pattern 1, 32%
experienced Pattern 2, 13% experienced
Pattern 3, and 16% experienced Pattern 4
(Fig. 1). On average, those in weight change
Pattern 1 initially lost about 3.4 kg and then
lost another 2.0 kg; the average net loss was
5.3 kg. The Pattern 2 group initially lost about
3.5 kg and then regained about half, resulting
in a net loss of 2.1 kg. The Pattern 3 group
initially gained about 1.8 kg and then lost
1.6 kg, resulting in a net gain of 0.2 kg. The
Pattern 4 group gained 3.3 kg on average,
about half during the first 18 weeks and half
during the second 18 weeks. Among those
randomized to canagliflozin, 52% and 4%
experienced weight change Patterns 1 and 4,
compared to 13% and 40% for glimepiride,




Weight change pattern was significantly related
to taking Action for weight loss at week 36
(Table 3). Subjects who experienced Patterns 1
and 2 were 2.2 and 1.7 times more likely to take
Action for weight loss at week 36, respectively,
versus those in the Pattern 4 group. Consistent
with previous research [31], baseline RTC was an
important predictor of future behavior (odds
ratio [OR] 4.4). Interestingly, self-efficacy was
statistically significant even after controlling for
baseline RTC. Baseline BMI, race, and
weight-related self-esteem were also
significantly related to taking Action for weight
loss as week 36. The OR for baseline HbA1c was
numerically less than 1 (P = 0.052), suggesting
lower HbA1c values may be related to taking
Action. Lower weight-related self-esteem was
related to taking Action, which may reflect the
need for some level of negative impact of weight
on self-esteem to necessitate Action.
Diet
Weight change pattern was significantly related
to taking Action for diet at week 36 (Table 3).
Compared to the Pattern 4 group, those who
experienced Pattern 1 were 1.9 times more
likely to follow a diet. Baseline RTC was an
important predictor of taking Action for diet at
week 36 (OR 6.66). Women were 1.4 times more
likely to take Action for diet versus men, and
smokers were significantly less likely to take
Action for diet. Self-efficacy for following a diet
and resisting food temptations was related to
being in Action for diet at week 36.
Exercise
Subjects who experienced Pattern 1 were 2
times more likely to be taking Action for
exercise compared to those who experienced
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Pattern 4 (Table 3). As for the other self-care
behaviors, baseline RTC was an important
predictor of taking Action; taking Action for
exercise at baseline was related to an eight-fold
increase for taking Action at week 36. Despite
controlling for this relationship, self-efficacy for
exercise was a significant predictor of taking
Action.
Compliance with Ethics Guidelines
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
DISCUSSION
Weight loss is one of the healthy behaviors
recommended by the American Diabetes
Association for successful type 2 diabetes
management [1], but motivating patients to
lose weight and perform other healthy
behaviors is challenging. Part of the problem
in motivating people to perform healthy
behaviors is the lack of a perceivable
relationship between these day-to-day
activities and events that may occur many
years in the future [33].
In spite of these challenges, some patients do
lose weight. While weight loss and weight
maintenance among people with type 2
diabetes is infrequent in everyday clinical
practice, new classes of antihyperglycemic
medications, such as SGLT2 inhibitors, have
been shown to cause weight loss in randomized
controlled trials through their mechanism of
action (i.e., patients experience a net caloric loss
of approximately 400 kcal/day as a result of
increased urinary glucose excretion) [28–30].
The majority of weight loss with SGLT2
inhibitors is experienced in the first 12 weeks
after initiation of treatment [23]. However,
some people continue to lose weight over
time, and others are able to maintain a
healthy weight long after 12 weeks [23]. For
these people, the psychological effect of the
initial weight loss may be different than for
those who do not continue to lose or maintain
weight. In this study, for about 90% of subjects,
the first report of action was prior to or
concurrent with the first recorded weight loss
for all actions explored. Thus, we do not believe
that the action typically precedes weight loss,
but more frequent measurement would be
required to clarify the temporal relationship.
The current work highlights the importance
of weight change patterns for performance of
diabetes self-care. Because some therapies have
been associated with weight gain while others
are considered weight neutral, and more
recently approved options are associated with
weight loss [34], treatment choice can influence
weight change patterns. When a therapy
Table 2 Number (%) of subjects who were taking action
for weight loss, diet, and exercise at baseline and week 36
Baseline Week 36
pre-Action Action Total
Taking Action to lose weight (N = 1182)
pre-Action 228 19% 246 21% 474 40%
Action 127 11% 581 49% 708 60%
Total 355 30% 827 70% 1182 100%
Taking Action to follow diet (N = 1182)
pre-Action 207 18% 241 20% 448 38%
Action 78 7% 656 55% 734 62%
Total 285 24% 897 76% 1182 100%
Taking Action to exercise (N = 1174)
pre-Action 324 28% 232 20% 556 47%
Action 79 7% 539 46% 618 53%
Total 403 34% 771 66% 1174 100%
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associated with weight gain is prescribed,
additional support that encourages self-care
behaviors may be required to mitigate this
effect.
Clinical measures that are important for the
management of type 2 diabetes are increasingly
being evaluated based on trajectories or patterns
[35–37]. For example, studies by Feldstein et al.
have shown that weight loss trajectories after
diagnosis of type 2 diabetes are associated with
improvements in glycemic and blood pressure
control, while higher stable weight and weight
gain patterns are associated with poorer
glycemic and blood pressure outcomes [35,
36]. Walraven et al. [37] tracked HbA1c
trajectories and observed that unfavorable
glycemic outcomes were more common
among younger patients and among those
with higher baseline HbA1c levels and longer
duration of diabetes.
Although patterns of change in clinical
variables have been examined, our motivation
for defining weight change patterns was to
more appropriately reflect the experience of
people living with type 2 diabetes. In addition
to considering weight as a risk factor for future
micro- and macrovascular complications, we
hope that health care professionals will also
Fig. 1 Change in weight from baseline by weight pattern. Data are mean ± standard deviation from baseline
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understand weight as a process that people with
type 2 diabetes are experiencing and using to
make decisions about whether they will
perform diabetes self-care behaviors.
Because longitudinal weight data are
collected in clinical practice, health care
professionals can look back further than the
last visit to get an overall view of weight
patterns (as in pediatrics). Accurate
determination of weight patterns could be
supplemented by the addition of self-reported
weight information in between visits. The
increasing popularity of health-tracking
applications could be leveraged in this
capacity. Speaking with people about personal
data that they may be tracking may improve
responsiveness to suboptimal results and
expedite adjustments to treatments and/or the
Table 3 Relationship between weight, baseline covariates, and readiness to change at week 36
Lose weight Follow diet Exercise
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Weight trajectories
Pattern 1 (vs. Pattern 4) 2.24 1.49, 3.37 1.92 1.23, 3.02 2.01 1.31, 3.09
Pattern 2 (vs. Pattern 4) 1.73 1.14, 2.61 \0.001 1.30 0.83, 2.04 0.003 1.34 0.86, 2.07 0.005
Pattern 3 (vs. Pattern 4) 1.16 0.71, 1.89 0.88 0.51, 1.51 1.17 0.69, 1.99
Self-efﬁcacy (vs. no self-efﬁcacy)a 1.64 1.21, 2.23 0.001 1.93 1.38, 2.69 \0.001 2.11 1.56, 2.85 \0.001
Action (vs. pre-Action)a 4.40 3.32, 5.84 \0.001 6.66 4.83, 9.19 \0.001 7.96 5.81, 10.90 \0.001
Age (1 year) 1.00 0.99, 1.02 0.738 1.00 0.98, 1.02 0.864 0.99 0.98, 1.01 0.379
Female (vs. male) 1.22 0.90, 1.63 0.197 1.40 1.01, 1.94 0.046 0.97 0.71, 1.31 0.840
Caucasian race (vs. non-Caucasian) 0.58 0.41, 0.83 0.003 1.08 0.74, 1.57 0.694 1.02 0.71, 1.47 0.897
Smoker (vs. non-smoker) 1.09 0.71, 1.67 0.680 0.62 0.40, 0.96 0.031 0.74 0.48, 1.15 0.184
BMI (1 unit)a 1.09 1.05, 1.13 \0.001 1.02 0.98, 1.05 0.385 1.00 0.96, 1.03 0.785
HbA1c (per 1%)a 0.84 0.71, 1.00 0.052 0.95 0.79, 1.16 0.632 1.07 0.89, 1.29 0.450
History of depression (vs. no
history)a
0.83 0.48, 1.43 0.500 0.63 0.36, 1.11 0.109 0.83 0.47, 1.47 0.527
Weight-related self-esteem
(1 point)b
0.82 0.66, 1.03 0.087 1.06 0.85, 1.33 0.604 0.97 0.78, 1.20 0.788
Weight-related physical function
lowest quartile (vs. higher)b
0.82 0.55, 1.23 0.347 1.07 0.71, 1.64 0.739 0.80 0.54, 1.20 0.283
General mental functional statusc 0.99 0.97, 1.00 0.103 1.00 0.98, 1.02 0.891 1.00 0.99, 1.02 0.885
General physical functional statusc 0.99 0.97, 1.01 0.371 1.00 0.97, 1.02 0.781 0.99 0.97, 1.01 0.540
BMI body mass index, CI conﬁdence interval, OR odds ratio
a Measured at baseline
b Based on Impact of Weight on Quality of Life–Lite self-esteem and physical function subscales
c Based on the Short-Form 36 physical component score and mental component score
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need to provide additional diabetes
management support and education. In
addition, exploring how people feel about
their weight pattern may help to
operationalize the central role of the patient in
collaborative disease management efforts.
An important result of this work is the
identification of a relationship between
self-efficacy and behaviors, despite adjustment
for prior behaviors. The obvious risk for those
already engaging in healthy behaviors is that
they might stop. Therefore, it is important to
commend and encourage persistent and
consistent performance of self-care so that
people can appreciate the link between their
behaviors and outcomes [8]. MI techniques can
help facilitate the identification of specific
behaviors where self-efficacy may be higher to
guide collaboration and planning for
performance of these target behaviors [3, 11].
We focused on weight loss and not
treatment effect, since our goal was to describe
how weight loss might impact future behaviors.
Because the primary mechanism of action of
SGLT2 inhibitors is to cause excretion of excess
glucose in urine, the glycemic efficacy of
canagliflozin is linked to the causal pathway
for weight loss. While the results of Phase 3
trials showed overwhelmingly greater weight
loss with canagliflozin compared with placebo
and active comparators, many individuals in
the comparator arms did lose weight during the
studies [22, 23, 28–30]. We acknowledge that
one limitation of this study is that the amount
of weight change experienced by the people in
this sample is not typical in real-world settings;
therefore, the patterns of weight over time in a
group of people without an intervention could
be different.
‘Patient-centered care’ has become part of
the lexicon for the management of diabetes [2].
The American Diabetes Association/European
Association for the Study of Diabetes guidelines
note, ‘‘Ultimately, it is patients who make the
final decisions regarding their lifestyle choices
and, to some degree, pharmaceutical
interventions they use; their implementation
occurs in the context of the patients’ real lives
and relies on the consumption of resources
(both public and private) [2].’’ This work
provides empirical support for some small, but
meaningful, patient-centered actions that
practitioners can take today. Specifically, these
include tracking weight change patterns over
time, assessing self-efficacy for healthy
behaviors, and being aware of the relationship
between weight changes and diabetes self-care
behaviors.
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